porpotany.
All rights received. No rouse allowed without permission
All rights reserved. No reuse allowed without permission.
•

1	Whole-Exome sequencing identifies a Type 2 Diabetes candidate mutation in <i>PTPRF</i>
2	Running title: <i>PTPRF</i> and Type 2 Diabetes
3	
4	Erik J.M. Toonen ¹ , Michael Kwint ² , Alexander Hoischen ² and Cees J. Tack ³
5	
6	Affiliations
7	¹ R&D department, Hycult Biotech b.v., Fronstraat 2a, 5405 PB, Uden, The Netherlands
8	² Departments of Human Genetics and ³ Internal Medicine, Radboud University Medical
9	Center (Radboudumc), Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The
10	Netherlands.
11	
12	Corresponding Author
13	Cees J. Tack (Cees.Tack@radboudumc.nl), Department of Internal Medicine, Radboud
14	University Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel:
15	+31 24 3618819
16	
17	Funding
18	E.T. was supported by an EFSD/Novo Nordisk research grant provided by the European
19	Foundation for the Study of Diabetes (EFSD) and by a grant of the Else-Kröner-
20	Fresenius-Stiftung.
21	
22	
23	
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Author contributions

- 27 ET: designed the study, performed the experiments, analyzed and interpreted the results,
- 28 wrote the manuscript. MK: performed the experiments, analyzed and interpreted the
- 29 results. AH: designed the study, analyzed and interpreted the results, revised the
- 30 manuscript. CT: designed the study, analyzed and interpreted the results, revised the
- 31 manuscript.
- 32
- **Word count:** 3404 (excl. references)

34 Abstract

35

Objectives: Identification of genetic factors involved in Type 2 diabetes mellitus 36 (T2DM) has been challenging. While genome-wide association studies (GWAS) have 37 identified over 60 loci associated with T2DM, these variants only explain a small 38 proportion of the total heritability of the disease. Whole-exome sequencing has become 39 a powerful approach to identify genetic variants that are not captured by GWAS. We 40 applied exome sequencing to identify causal genetic variants in a family with a 2-41 generation history of T2DM characterized by substantial insulin resistance, hypertension 42 43 and isolated hypertriglyceridemia. Methods: Exome sequencing was performed on genomic DNA of two affected family members. Twenty-four identified variants that were 44 present in both family members were further tested for segregation in all other family 45 members by Sanger sequencing. Results: Three rare missense variants, located in the 46 genes PTPRF, FUCA1 and FBXO30, were present in all affected family members but 47 also in one unaffected family member. Protein-protein interaction analysis showed that 48 49 *PTPRF* strongly interacts with several members of the insulin signaling pathway.

Conclusions: Our results suggest that the variant in the *PTPRF* gene might be causal for
an unusual T2DM subtype that is characterized by a severe insulin resistance and isolated
hypertriglyceridemia.

53

Keywords: Whole-exome sequencing, Insulin resistance, Genetics of Type 2 Diabetes,
Hypertriglyceridemia, Rare genetic variants.

56 Introduction

57

Type 2 diabetes mellitus (T2DM) is a complex multifactorial trait where both 58 environmental and genetic factors contribute to the pathogenesis of the disease. Based on 59 twin and segregation studies, the heritability of type 2 diabetes has been estimated to be 60 between 36 and 83 percent [1, 2]. Large-scale genome-wide association studies (GWAS) 61 62 have contributed towards understanding the inherited basis of diabetes. In the past few years, GWA studies have identified over numerous loci associated with T2DM [3-7]. 63 However, these identified genetic variants account for less than 6 percent of the 64 65 heritability estimated from family studies [8]. Because these common variants explain only a small fraction of the estimated heritability, it has been hypothesized that rare 66 genetic variants with large effect sizes contribute to the genetic predisposition of T2DM. 67 Traditional genotyping platforms used in GWAS are primarily designed to capture 68 common genetic polymorphisms but offer poor coverage of rare genetic variants, hence 69 rare disease variants with large effect sizes are easily missed [9]. Approaches other than 70 71 GWAS are necessary to identify the remaining genetic variants underlying the 72 pathogenesis of type 2 diabetes in order to improve diagnosis and treatment strategies.

Recently, whole-exome sequencing has become a powerful strategy to identify low-frequency and rare variants not captured by GWAS [10]. Sequencing of all genes (exome) is an approach relying on the hypothesis that functional disease-associated variation resides in the coding regions. Whole-exome sequencing has proven to be valuable for identifying mutations responsible for monogenic diseases [11] and emerging reports show that exome sequencing can also be applied to uncover variation associated with complex human traits [12, 13]. While T2DM consists of both decreased insulin

80	secretion and reduced insulin action (insulin resistance), most genetic defects identified
81	so far relate to insulin secretion and genetic factors in obesity-induced insulin resistance
82	seem to be underreported [14].
83	In the present study, we apply exome sequencing to identify genetic variants that
84	may have a role in disease susceptibility in a family with a 2-generation history of type 2
85	diabetes, with an unusual phenotype characterized by pronounced insulin resistance and

86 hypertriglyceridemia.

87 Methods

88

89 *Family members*

We recruited a family with a 2-generation family history of T2DM. The index cases were
under chronic diabetes care in the hospital. Due to privacy reasons, the pedigree is not
published, please contact the corresponding author for further information.

93

94 *Case presentations*

The index case presented with diabetes in his late thirties with a six months period of 95 weight loss (14 kg) and balanitis. Body weight at presentation 80.5 kg, height 1.73 (BMI 96 26.7 kg/m²), blood pressure 150/100. Laboratory analysis revealed HbA_{1c} 12.5%, ALAT 97 slightly elevated, urine ketones negative. Patient started oral combination therapy (SU 98 99 and metformin), with temporary improvement, but secondary glycemic failure after approximately 2 years. Before start of insulin his laboratory parameters were: HbA_{1c}: 100 9.2%, total cholesterol 5.3, Triglycerides 4.9, HDL-cholesterol 0.70, LDL 2.51 mmol/L 101 102 (all fasting and without statin), fasting insulin level: 30 mU/L, C-peptide: 1.54 nmol/L, ASAT 21, ALAT 39, urine albumin 20 mg/L. Patient was started on insulin, eventually 103 104 administered by pump, up to 140 U/day (body weight increased to 94 kg, BMI 31.4 105 kg/m^2). His triglyceride levels remained elevated. See Table 1 for details. 106 A relative was diagnosed with diabetes in his sixties during routine medical examination.

He was overweight (weight 87.5 kg, height 1.78, BMI 27,6 kg/m²) and had hypertension,

108 micro-albuminuria, hypertriglyceridemia and low HDL-cholesterol. He was eventually

treated with insulin, up to 160 U/day. He always had elevated triglyceride levels.

The clinical phenotype of affected family members was characterized by substantial 110 111 insulin resistance, hypertension and hypertriglyceridemia without hypercholesterolemia. Data from one affected relative were retrieved from another hospital. Data from an 112 unaffected relatives were obtained during a short hospital visit, data from one unaffected 113 relative were obtained through his GP and by telephone. In family members with diabetes, 114 detailed information regarding onset of diabetes, complications and treatment was 115 obtained. In unaffected family members, BMI and blood pressure was measured and 116 fasting glucose, and HbA1c (to exclude diabetes) and lipids levels were measured. Results 117 are depicted in Table 1. There was no information suggesting consanguineous marriage 118 119 in the family.

120

121 Non-related diabetes subjects

122 To validate our initial results obtained from the analysis of the family members, we selected 24 non-related subjects who matched the characteristics of the affected family 123 members (insulin > 1U/kg or >100 U/day; TG > 1,5 mmol/l; BMI < 35 kg m2). Subjects 124 were selected from the Diabetes Pearl patient cohort. This cohort is a large, well-125 characterized observational cohort of type 2 diabetes patients. The Diabetes Pearl cohort 126 127 is a collaborative biobank initiative from the Dutch University Medical Centers (www.parelsnoer.org) [15]. DNA samples were retrieved from the Biobank after approval 128 of the ethics committee. 129

130

131 Whole-Exome sequencing

Exome sequencing was essentially performed as described previously [16, 17]. In brief,
exome enrichment was performed using the SureSelect Human Exon 50-Mb Kit (Agilent,

Santa Clara, CA, USA), covering approximately 22.000 genes, followed by SOLiD4
sequencing (Life Technologies, Carlsbad, CA, USA). Reads were mapped to the hg19
reference genome using SOLiD LifeScope software version 2.1. All nonsynonymous
variants shared in both affected individuals and absent or with very low frequency (0.1%)
in dbSNP, were further investigated in healthy and affected family members.

139

140 Sanger Sequencing

Nonsynonymous variants identified by exome sequencing were tested in healthy and affected family members for co-segregation by traditional Sanger sequencing. Forward and reverse PCR primers for each exon in which the variant was located were selected in an intronic sequence 50 bp away from the intron/exon boundaries. Unique primers were designed using the Primer3 software. PCR products were verified on 2% agarose gel, purified using ExoSAP-IT (Affymetrix, Santa Clara, CA, USA) and analyzed on ABI3730 genetic analyzers (Life Technologies, Carlsbad, CA, USA).

148

149 *Ion torrent library preparation and sequencing*

All 32 coding exons of the PTPRF gene were analyzed in 24 unrelated diabetes patients 150 151 who matched the clinical characteristics of the affected family members. The screening of 24 patients for variants in the PTPRT gene was carried out by using an Amplicon-based 152 deep-sequencing approach on the Ion PGM sequencer (Life Technologies, Carlsbad, CA, 153 154 USA). PCR amplicons were generated per sample using standard PCR protocols. Primer 155 sequences are available upon request. PCR products per sample were pooled, and subsequently sheared to 200-bp fragments by the use of Covaris E210 (Covaris Inc.). 156 157 Library preparation was performed using the Ion Xpress[™] Plus Fragment Library Kit in

combination with the Ion Xpress Barcode adapters 1-96 kit. Emulsion PCR and enrichment were carried out on the Ion OneTouch System using the Ion PGM TemplateOT2 200 Kit as described by the manufacturer. Sequencing was performed using the 200bp kitv2, with Ion Sphere particles loaded to an Ion318TM chip (Life Technologies Carlsbad, CA, USA). Raw sequencing reads were mapped to the hg19 genome using the Torrent Server with the use of the Torrent suite software. FASTQ files were subsequently analyzed and visualized in SeqNext (JSI Medical systems).

165

166 Protein-protein interaction analysis

Protein-protein interactions (PPI) were identified using the STRING database (STRING v9.1; http://string-db.org/) [18]. STRING builds functional protein association networks based on compiled available experimental evidence. A confidence score is assigned to each identified protein–protein association and this score will increase when an association is supported by several types of evidence. In this study, only PPI are shown that yielded a high confidence score (≥ 0.7).

173

174 *Ethics*

All family members were informed about the goal of the study and consented toparticipation.

- 178
- 179
- 180
- 181

182 **Results**

183

184 Characteristics of family members

185 Characteristics of affected and unaffected family members are shown in Table 1.

186

187 Whole-Exome sequencing identifies variants within the PTPRF and ASXL1 genes

188 Exome sequencing was performed on genomic DNA of two family members with an average 46- and 81-fold coverage leading to 85.2% and 87.9% of the exome with at least 189 10-fold coverage, respectively. We identified 38,067 and 39,293 genetic variants per 190 proband in the two family members, respectively. Variants were annotated by a 191 bioinformatics pipeline as previously described [16]. In addition, the variant had to be 192 present in at least 20-80% of all reads suggestive of heterozygous changes in a dominant 193 194 model of disease. Subsequently, genetic variants were prioritized based on predicted amino acid consequences and overlap with common genetic variants (listed in dbSNP 195 196 version 135 and/or present in an in-house database containing >10,000 analyzed exomes 197 of predominantly European ancestry). All filter steps are shown in Supplementary Table 198 1.

We identified 21 unique non-synonymous variants present in both affected family members that were present in genes with known expression in adipose tissue (Table 2, Supplementary Table 1). All 21 variants were tested for segregation in all other family members by Sanger sequencing (Table 3). Two rare missense variants were present in all affected family members but also in one unaffected family member. Variants c.3614A>G (rs200885607; p.(N11965S); located in the gene *Protein tyrosine phosphatase, receptor type F (PTPRF;* NM_002840)) and c.904C>T p.(R302C); located in the gene *ASXL*

transcriptional regulator 1 (ASXL1; NM 015338)) were also present in the non-affected 206 207 family member II/4 (Table 3). The c.3614A>G variant within *PTPRF* was detected once in the in genome-wide sequence data from the 1000 Genomes Project which include the 208 genomes of 1088 people (or 2176 chromosomes) [19]. The variant was present at very 209 210 low frequency in public exome datasets, e.g. ExAc browser frequency 12/121398 alleles, 211 i.e. allele frequency of 9.885 x 10⁻⁵; with 7/66730 alleles in Non-Finish Europeans (0.0001049 allele frequency) (http://exac.broadinstitute.org/[August 2019]) and also with 212 very low allele frequency in the in-house exome database (0.00045 in > 8000 exomes). 213 The ASXL1 variant was never observed in ExAc nor in the in-house database. In silico 214 215 predictions for both variants can be seen in Supplementary Table 2.

216

217 *PTPRF strongly interacts with proteins involved in insulin signaling.*

218 To investigate/identify in which biological processes and pathways the genes *PTPRF* and 219 ASXL1 are involved, we used the STRING database to search for predicted and published protein-protein interactions. Analysis showed that *PTPRF* strongly interacts with several 220 221 members of the insulin signaling pathway. High confidence scores were assigned to the 222 interactions between PTPRF and Insulin receptor (INSR) and Insulin receptor substrate 223 1 and 2 (IRS1 and 2) (Table 4, Figure 1A). Indeed, PTPRF was demonstrated to be expressed in several insulin sensitive tissues where it interacts with the insulin receptor 224 225 and dephosphorylates its tyrosine-kinase domain, thereby inhibiting its activation and 226 downstream signaling [20]. These results point out to an important role for *PTPRF* in insulin signaling. Protein-protein interaction analysis also revealed that ASXL1 did not 227 228 interact with proteins involved in insulin signaling, glucose metabolism or other

biological processes that are likely to play a role in the pathogenesis of type 2 diabetes(Table 4 and Figure 1B).

231

232 Investigation of the PTPRF gene in an additional cohort of T2DM patients

233 The results described above clearly pointed out to PTPRF as a strong candidate gene for this T2DM phenotype. To validate our results, we investigated the *PTPRF* gene for the 234 235 possible presence of genetic variants in an additional cohort of 24 unrelated T2DM patients. These patients were selected based upon disease characteristics that matched the 236 characteristics of the affected family members (insulin > 1U kg or 100 U/day; TG > 1,5 237 238 mmol/l; BMI < 35 kg m²). All coding exons of the *PTPRF* gene were sequenced in these 239 24 patients by the use of Ion torrent sequencing. The c.3614A>G variant was not present in these 24 patients. Also no additional rare variants were detected in this cohort. 240

241

242 Discussion

243

244 In the present study, we applied whole-exome sequencing to identify genetic variants 245 possibly involved in disease susceptibility in a family with T2DM, characterized by 246 substantial insulin resistance, hypertension and hypertriglyceridemia in the absence of 247 hypercholesterolemia. We identified the rare variant c.3614>G, located within the PTPRF gene, as a novel candidate susceptibility variant. Sequencing of all coding exons of the 248 249 *PTPRF* gene in a cohort of 24 non-related T2DM patients did not reveal any additional variants. Our results suggest that the c.3614A>G variant might play a role in an unusual 250 251 T2DM subtype that is characterized by a severe insulin resistance and "isolated" 252 hypertriglyceridemia. Identification of genetic variants responsible for specific forms of

diabetes provide new insights regarding underlying disease aetiology. These new insights
may help to improve diagnosis and to optimize treatment strategies in these specific
T2DM subtypes.

The c.3614A>G variant was detected in all affected family members but also in 256 one unaffected family member. Although this family member was not diagnosed with 257 type 2 diabetes, his triglyceride levels were elevated. All family members with diabetes 258 259 had episodes with grossly elevated TG levels (>10 mmol/L), fairly independent of age, but occasionally also showed less elevated TG levels. TG level was, however, always 260 above the normal range. TG level in the genetically affected family member without 261 262 diabetes was moderately elevated in one single blood sample. Perhaps this person had a 263 combination of relative active lifestyle and excellent beta-cell function, resulting in absence of diabetes. Additionally, T2DM is a multifactorial disease in which both genetic 264 265 as environmental factors play a role. Another reason why this individual carries the c.3614A>G variant but was not diagnosed with T2DM might be reduced penetrance. As 266 often seen for multifactorial diseases with a heritable component, the c.3614A>G variant 267 268 may have reduced penetrance, meaning that some individuals fail to express the trait, even 269 though they carry the allele. The degree of penetrance is difficult to determine and is often 270 age related. Given that the onset of symptoms in T2DM are age related and affected by 271 both genetic as well as environmental factors such as nutrition, it is possible that this 272 individual will develop the disease in the near future, although he is currently older than 273 the age at which the diabetes was diagnosed in his brothers.

Although we cannot exclude the variant located in *ASXL1* as a candidate, the evidence for *PTPRF* as a candidate gene for T2DM is more convincing. Our finding that a genetic variant within *PTPRF* may be involved in the pathogenesis of type 2 diabetes is

supported by earlier studies. Miscio and co-workers investigated whether common 277 polymorphisms within the PTPRF gene were associated with insulin resistance. They 278 identified a single nucleotide polymorphism (SNP) within the promoter region (-127T>A; 279 rs3001722) in which the A allele (minor allele) was associated with lower body mass 280 281 index (BMI), waist circumference and mean blood pressure in a cohort of 589 unrelated non-diabetic subjects. In addition, the A allele was associated with lower triglycerides, 282 glucose and insulin levels during an oral glucose tolerance test (oGTT) in an independent 283 cohort of 307 unrelated non-diabetic individuals [21]. Menzaghi and co-workers report 284 an association between the SNP 2518A>G (rs2782641), located within intron 3, and 285 286 cononary artery disease (CAD) in a T2DM patient cohort including 592 individuals [22]. 287 To our knowledge, the c.3614A>G variant has not been reported in literature in relation to T2DM. These studies, together with our results, suggest that genetic variants within 288 289 PTPRF are contributing to insulin resistance and T2DM in at least a subpopulation of 290 patients.

PTPRF is a receptor-type transmembrane protein tyrosine phosphatase (PTPase) 291 292 that is expressed in several insulin target tissues [23]. It physically interacts with the 293 insulin receptor and dephosphorylates its tyrosine-kinase domain thereby inhibiting 294 insulin signaling [24]. Transgenic mice overexpressing *PTPRF* are insulin resistant [25] 295 and, conversely, PTPRF knock-out mice are characterized by increased insulin sensitivity [26]. PTPRF is therefore a potential candidate gene for insulin resistance. Regarding 296 297 ASXL1, no studies were reported showing evidence that ASXL1 is involved in the 298 pathogenesis of T2DM.

Most studies investigating the genetic background of T2DM are focusing on identifying common variants that are associated with the disease [8, 27-29]. However,

most studies have not been particularly successful in discovering new disease genes. As 301 a consequence, the rare variant hypothesis [30, 31], which states that rare variants with 302 large effects are the primary drivers of common diseases, has received renewed attention. 303 Studies investigating Mendelian diseases have demonstrated that a family-based 304 305 approach is a good method to detect these rare variants with relatively high impact on 306 disease [32]. Rare variants are not present in the general population at any reasonable 307 frequency and an advantage of a family-based study is that more observations of a rare variant can be made in large families. However, type 2 diabetes is a late-onset disease and 308 recruiting such families is challenging. We identified this family because of the unusual 309 310 phenotype of the index patient, and noted the familial existence of the combination of severe insulin resistance and "isolated" hypertriglyceridemia: hypertriglyceridemia in the 311 absence of hypercholesterolemia. As expected, hypertriglyceridemia was associated with 312 313 decreased HDL-cholesterol levels. In this study, we used the family-based approach combined with whole-exome sequencing to detect variants that may have a role in 314 susceptibility for the disease in this family. We were able to identify a rare variant located 315 316 in a strong T2DM candidate gene, which suggests that the family-based approach 317 combined with whole-exome sequencing may be a useful strategy to investigate the 318 genetic background of type 2 diabetes.

While our findings suggest that the c.3614A>G variant in *PTPRF* may underly the phenotype of the this family, we were unable to identify a second family within our facility that resembles the disease characteristics observed in this first family, despite sharing this as a candidate gene via genematcher.com [33, 34]. In addition, no variants in *PTPRF* were identified in a patient cohort of 24 unrelated T2DM patients who phenotypically matched the characteristics of the affected family members. Our study

lacks confirmation through functional studies, which should be included in future 325 326 investigations. We realize that it is possible that the identified variant is a false positive result. However, we would like to stress that the variant in *PTPRF* was identified using 327 an unbiased, non-candidate gene driven, whole exome-wide approach and that the gene 328 329 is known to be involved in insulin signaling and associated with metabolic disturbances. To our opinion, this suggests that PTPRF is a potential candidate gene that, at least, 330 should be added to the discussion regarding genetic variants underlying T2DM. In that 331 light, it might be best to see this report as a case report providing researchers and 332 clinicians the opportunity to respond and set up collaborations in order to identify 333 334 additional cases/families.

335 In summary, we applied whole-exome sequencing to identify genetic variants possibly involved in T2DM disease susceptibility in a family with highly aggregated type 336 337 2 diabetes. Our results suggest that the c.3614A>G variant in the *PTPRF* gene play a role in an unusual T2DM subtype that is characterized by a severe insulin resistance and 338 isolated hypertriglyceridemia. These results indicate that combining the family-based 339 340 approach with whole-exome sequencing may be a useful strategy to further unravel the genetic background of type 2 diabetes. The genetic variant identified within this study 341 342 represents a promising candidate for stratification of T2DM patients regarding mild or 343 severe insulin resistance. Follow-up studies are needed to confirm that the identified variant in the PTPRF gene is indeed responsible for severe insulin resistance and isolated 344 345 hypertriglyceridemia and to further unravel the precise working mechanism responsible for this unusual T2DM phenotype. If several independent studies are able to confirm our 346 initial results, this genetic variant may have additional value for diagnosis and to optimize 347

- treatment strategies in patients with this unusual T2DM subtype that is characterized by
- severe insulin resistance and isolated hypertriglyceridemia.

350 List of abbreviations

351

352 ALAT: alanine aminotransferase, ASAT: Aspartaat-aminotransferase, BMI: b	body mass
--	-----------

- 353 index, CAD: coronary artery disease, GP: general practitioner, GWAS: genome-wide
- association study, HbA1c: hemoglobin A1c, HDL: high-density lipoprotein, LDL: low-
- density lipoprotein, oGTT: oral glucose tolerance test, PCR: polymerase chain reaction,
- 356 PPI: protein-protein interaction, SNP: single nucleotide polymorphism, SU:
- 357 Sulphonylureas, T2DM: Type 2 diabetes mellitus, TG: triglycerides

358

359 Acknowledgements

360

361 The authors would like to thank Lisenka E.L.M. Vissers, Petra de Vries, Marloes

362 Steehouwer and Christian Gilissen for their help and advice during this study. The

- authors are very grateful to the patients and family members who made it possible to
- 364 perform this study.

365

366 Funding

E.T. was supported by an EFSD/Novo Nordisk research grant provided by the European
Foundation for the Study of Diabetes (EFSD) and by a grant of the Else-KrönerFresenius-Stiftung.

370

- 371 Conflicts of interests
- 372 None declared

Declarations

- *Ethics approval and consent to participate*
- 377 The authors state that they have obtained appropriate institutional review board approval
- 378 or have followed the principles outlined in the Declaration of Helsinki for all human or
- animal experimental investigations. All family members were informed about the goal of
- the study and consented to participation. Study was approves by the The local Medical
- 381 Ethical Committee, Commissie Mensgebonden Onderzoek (CMO) regio Arnhem-
- 382 Nijmegen.
- *Consent for publication*
- 385 Consent to publish was obtained from all individuals.
- *Availability of data and material*
- 388 Please contact author for data requests

398 **References**

- Kaprio, J., et al., Concordance for type 1 (insulin-dependent) and type 2 (noninsulin-dependent) diabetes mellitus in a population-based cohort of twins in
- 401 *Finland*. Diabetologia, 1992. **35**(11): p. 1060-7.
- 402 2. Diabetes mellitus in twins: a cooperative study in Japan. Committee on Diabetic
- 403 *Twins, Japan Diabetes Society.* Diabetes Res Clin Pract, 1988. **5**(4): p. 271-80.
- 404 3. O'Rahilly, S., I. Barroso, and N.J. Wareham, *Genetic factors in type 2 diabetes:*405 *the end of the beginning?* Science, 2005. **307**(5708): p. 370-3.
- 406 4. Witka, B.Z., et al., *Type 2 Diabetes-Associated Genetic Polymorphisms as*407 *Potential Disease Predictors.* Diabetes Metab Syndr Obes, 2019. 12: p. 2689408 2706.
- Fuchsberger, C., et al., *The genetic architecture of type 2 diabetes*. Nature, 2016.
 536(7614): p. 41-47.
- 411 6. Moltke, I., et al., *A common Greenlandic TBC1D4 variant confers muscle insulin*412 *resistance and type 2 diabetes.* Nature, 2014. **512**(7513): p. 190-3.
- 413 7. Flannick, J., et al., *Exome sequencing of 20,791 cases of type 2 diabetes and*414 *24,440 controls.* Nature, 2019. **570**(7759): p. 71-76.
- 415 8. Morris, A.P., et al., *Large-scale association analysis provides insights into the*416 *genetic architecture and pathophysiology of type 2 diabetes.* Nat Genet, 2012.
 417 44(9): p. 981-90.
- 418 9. Lohmueller, K.E., et al., Whole-exome sequencing of 2,000 Danish individuals
- 419 *and the role of rare coding variants in type 2 diabetes.* Am J Hum Genet, 2013.
- **93**(6): p. 1072-86.

- 421 10. Holm, H., et al., A rare variant in MYH6 is associated with high risk of sick sinus
- 422 *syndrome*. Nat Genet, 2011. **43**(4): p. 316-20.
- **423** 11. Ng, S.B., et al., *Exome sequencing identifies the cause of a mendelian disorder*.
- 424 Nat Genet, 2010. **42**(1): p. 30-5.
- 425 12. Samocha, K.E., et al., *A framework for the interpretation of de novo mutation in*426 *human disease*. Nat Genet, 2014.
- 427 13. Bernier, R., et al., *Disruptive CHD8 Mutations Define a Subtype of Autism Early*428 *in Development*. Cell, 2014. **158**(2): p. 263-76.
- 429 14. Grarup, N., et al., Genetic susceptibility to type 2 diabetes and obesity: from
- 430 *genome-wide association studies to rare variants and beyond.* Diabetologia, 2014.
- **431 57**(8): p. 1528-41.
- 432 15. Van't, R.E., et al., *The Diabetes Pearl: Diabetes biobanking in The Netherlands*.
 433 BMC.Public Health, 2012. 12: p. 949.
- 434 16. Hoischen, A., et al., *De novo mutations of SETBP1 cause Schinzel-Giedion*435 *syndrome*. Nat Genet, 2010. 42(6): p. 483-5.
- 436 17. van, d., V, et al., *STAT1 mutations in autosomal dominant chronic mucocutaneous*437 *candidiasis.* N.Engl.J.Med., 2011. 365(1): p. 54-61.
- Franceschini, A., et al., *STRING v9.1: protein-protein interaction networks, with increased coverage and integration.* Nucleic Acids Res, 2013. 41(Database
 issue): p. D808-15.
- 441 19. Genomes Project, C., et al., *A map of human genome variation from population-*442 *scale sequencing*. Nature, 2010. 467(7319): p. 1061-73.
- 443 20. Hashimoto, N., et al., *Insulin receptor protein-tyrosine phosphatases. Leukocyte*444 *common antigen-related phosphatase rapidly deactivates the insulin receptor*

445 kinase by preferential dephosphorylation of the receptor regulatory domain. J

446 Biol Chem, 1992. **267**(20): p. 13811-4.

44721.Miscio, G., et al., The allelic variant of LAR gene promoter -127 bp T-->A is448associated with reduced risk of obesity and other features related to insulin

449 *resistance.* J Mol Med (Berl), 2004. **82**(7): p. 459-66.

- 450 22. Menzaghi, C., et al., *The protein tyrosine phosphatase receptor type f (PTPRF)*451 *locus is associated with coronary artery disease in type 2 diabetes.* J Intern Med,
 452 2008. 263(6): p. 653-4.
- Tsujikawa, K., et al., *Distinct functions of the two protein tyrosine phosphatase domains of LAR (leukocyte common antigen-related) on tyrosine dephosphorylation of insulin receptor.* Mol Endocrinol, 2001. 15(2): p. 271-80.
- 456 24. Goldstein, B.J., et al., *Regulation of the insulin signalling pathway by cellular*457 *protein-tyrosine phosphatases*. Mol Cell Biochem, 1998. **182**(1-2): p. 91-9.
- Zabolotny, J.M., et al., Overexpression of the LAR (leukocyte antigen-related)
 protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad
- 460 Sci U S A, 2001. **98**(9): p. 5187-92.
- 461 26. Ren, J.M., et al., *Transgenic mice deficient in the LAR protein-tyrosine*462 *phosphatase exhibit profound defects in glucose homeostasis*. Diabetes, 1998.
 463 47(3): p. 493-7.
- 464 27. Replication, D.I.G., et al., *Genome-wide trans-ancestry meta-analysis provides*465 *insight into the genetic architecture of type 2 diabetes susceptibility*. Nat Genet,
 466 2014. 46(3): p. 234-44.

- 467 28. Albrechtsen, A., et al., *Exome sequencing-driven discovery of coding*468 *polymorphisms associated with common metabolic phenotypes*. Diabetologia,
 469 2013. 56(2): p. 298-310.
- 470 29. Manning, A.K., et al., *A genome-wide approach accounting for body mass index*471 *identifies genetic variants influencing fasting glycemic traits and insulin*472 *resistance.* Nat Genet, 2012. 44(6): p. 659-69.
- 473 30. Bodmer, W. and C. Bonilla, *Common and rare variants in multifactorial*474 *susceptibility to common diseases.* Nat Genet, 2008. 40(6): p. 695-701.
- 475 31. Pritchard, J.K. and N.J. Cox, *The allelic architecture of human disease genes:*476 *common disease-common variant...or not?* Hum Mol Genet, 2002. 11(20): p.
 477 2417-23.
- 32. Saad, M. and E.M. Wijsman, *Power of family-based association designs to detect rare variants in large pedigrees using imputed genotypes.* Genet Epidemiol, 2014.
- **480 38**(1): p. 1-9.
- 481 33. Sobreira, N., et al., *GeneMatcher: a matching tool for connecting investigators*482 *with an interest in the same gene.* Hum Mutat, 2015. 36(10): p. 928-30.
- 483 34. Sobreira, N., et al., New tools for Mendelian disease gene identification: PhenoDB
 484 variant analysis module; and GeneMatcher, a web-based tool for linking
 485 investigators with an interest in the same gene. Hum Mutat, 2015. 36(4): p. 425-
- 486 31.

487

	Phenotype									
Family	Diabetes	AGE of	HT	AGE	BMI	Insulin	Total	Triglycerides	HDL-	LDL-
member		ONSET			(kg/m	dose	Cholesterol	(mmol/l)	cholesterol	Cholesterol
					²)	(U/kg)	(mmol/l)		(mmol/l)	(mmol/l)
1	Yes	60s	Yes	80s†	27	1.9	4.4 - 4.7	3.6 – 4.7	0.6	2.2
2	No		Yes	Late 80s	35	N/A	4.9	2.5	0.8	3.0
3	Yes [#]	20s	Yes	Late 50s	19	1.0	3.7	4.4 (max 25)	0.8	1.0
4	Yes	Late 30s	Yes	Late 50s	31	1.6	5.3	4.9	0.7	2.5
5	No		No	50s†	?	N/A				
6	No		Yes	50s	27	N/A	4.8	1.9	1.1	2.9
7	Yes [#]	Late 30s	Yes	50s	27	0.9	4.5	2.9	0.9	2.2
8	No		No	Late 40s	30	N/A	5.1	3.4	0.9	2.7

489 **Tabel 1.** Characteristics of family members

490 [#]denoted as type 1 diabetes but no auto-immunity tested; HT: hypertension; BMI: Body Mass Index

491 †Died at indicated age

Gene	Gene ID	Chromosome	Reference	Mutation	Start	End	Abberation	Reference Amino	Mutation Amino	Conservation
symbol					position	position		Acid	Acid	score
PDLIM5	NM_006457	chr4	С	Т	95561564	95561564	substitution	R	*	1.933
PARP6	NM_020214	chr15	G	А	72553972	72553972	substitution	Н	Y	9.711
KTN1	NM_004986	chr14	С	Т	56094742	56094742	substitution	Т	Ι	3.371
NEXN	NM_001172309	chr1	А	G	78399073	78399073	substitution	Е	G	8.789
PCNX	NM_014982	chr14	С	Т	71428992	71428992	substitution	Р	S	6.163
PTPRF	NM_002840	chr1	Α	G	44072041	44072041	substitution	Ν	S	-0.606
NPR1	NM_000906	chr1	Т	С	153660586	153660586	substitution	L	Р	1.801
DCAF8	NM_015726	chr1	Т	G	160209533	160209533	substitution	Q	Р	0.727
C10orf128	NM_001288742	chr10	G	А	50364232	50364232	substitution	S	L	-0.062
PYROXD1	NM_024854	chr12	А	G	21602560	21602560	substitution	K	Е	5.191
POLR2A	NM_000937	chr17	А	G	7417024	7417024	substitution	Q	R	1.397
CHD3	NM_001005271	chr17	Т	С	7810699	7810699	substitution	L	Р	0.563
PARD3B	NM_152526	chr2	С	G	206480223	206480223	substitution	R	G	3.724
LANCL1	NM_001136574	chr2	А	С	211306083	211306083	substitution	F	L	2.365
ASXL1	NM_015338	chr20	С	Т	31019407	31019407	substitution	R	С	4.337
PRMT2	NM_001242865	chr21	С	Т	48071838	48071838	substitution	L	F	-0.331
GOLIM4	NM_014498	chr3	С	Т	167728086	167728086	substitution	E	K	3.176
GTPBP2	NM_019096	chr6	С	А	43591700	43591700	substitution	Е	D	0.073
MATN2	NM_002380	chr8	Т	С	98991158	98991158	substitution	С	R	6.292
PRUNE2	NM_015225	chr9	G	A	79267561	79267561	substitution	R	W	1.445
AKNA	NM_030767	chr9	С	Т	117139699	117139699	substitution	G	R	-0.126

492 **Table 2.** Overview of the 21 unique nonsynonymous variants present in both affected family members.

⁴⁹³ *stop mutation; conservation score: PhyloP; measures acceleration (faster evolution than expected under neutral drift) as well as

494 conservation (slower than expected evolution). The absolute values of the scores represent –log p-values under a null hypothesis of neutral

evolution.

Gene symbol	Family member								
	1	2	3	4	5	6	7	8	
	Affected	Not affected	Affected	Affected	Not affected	Not affected	Affected	Not affected	
NFR1	AG	AA	AA	AG	AA	AG	AA	AA	
DCAF8	TT	-	-	TT	-	-	-	-	
C10orf128	GA	GG	GG	GA	GA	GG	GG	GG	
PYROXD1	AG	AA	AG	AG	AA	AA	AA	AA	
POLR2A	AG	AA	AA	AG	AA	AG	AA	AA	
CHD3	TC	TT	TT	TC	TT	TC	TT	TT	
PARD3B	CG	CC	CG	CG	CG	CG	CG	CC	
LANCL1	AC	AA	AC	AC	AC	AC	AC	AA	
ASXL1	СТ	CC	СТ	СТ	CC	СТ	СТ	CC	
PRMT2	СТ	CC	CC	CT	CT	CC	CC	СТ	
GOLIM4	СТ	CC	CT	CT	CT	CT	CT	CT	
GTPBP2	CC	-	-	CC	-	-	-	-	
MATN2	TC	TT	TC	TC	TC	TT	TT	TC	
PRUNE2	GA	GG	GG	GA	GA	GA	GA	GA	
AKNA	СТ	CC	CC	CT	CT	CT	CT	CC	
PDLIM5	СТ	CC	CC	CT	CC	CC	СТ	СТ	
PARP6	GA	GG	GG	GA	GA	GA	GG	GA	
KTN1	СТ	CC	CT	CT	CT	CC	СТ	CT	
NEXN	AG	AA	AG	AG	AG	AA	AG	AG	
PCNX	СТ	CC	CC	CT	CT	CC	СТ	CT	
PTPRF	AG	AA	AG	AG	AA	AG	AG	AA	

496 **Table 3.** Segregation of the 21 identified variants in all family members.

497 Exome sequencing was performed on genomic DNA of two family members. Segregation of the identified variants in family members was

498 investigated by the use of Sanger sequencing. The variants that were identified with exome sequencing in *DCAF8* and *GTPBP2* could not be

499 confirmed by Sanger sequencing in the family members. Therefore, Sanger sequencing for these variants in the rest of the family members

500 was not performed. Family members that were diagnosed with diabetes (affected) are indicated in grey.

Table 4. Predicted interaction partners for *PTPRF* and *ASXL1*.

	PTPRF	
Gene symbol	Gene name and function	Confidence score
PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1. Binds to the intracellular membrane-distal phosphatase domain of PTPRF. This interaction may regulate the disassembly of focal adhesion and thus help orchestrate cell-matrix interactions.	0.950
INSR	Insulin receptor. Binding of insulin to this receptor stimulates glucose uptake. Inhibiting/disrupting of insulin binding to <i>INRS</i> results in insulin resistance and T2DM. Polymorphisms within this gene are associated with insulin resistance and T2DM.	0.913
LRFN4	Leucine rich repeat and fibronectin type III domain containing 4; Promotes neurite outgrowth in hippocampal neurons	0.910
CTNNB1	Catenin (cadherin-associated protein), beta 1. The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells	0.889
IRS1	Insulin receptor substrate 1. Located downstream of <i>INSR</i> in the insulin signaling pathway. Insulin activates <i>INSR</i> , which phosphorylates and recruits different substrate adaptors such as the IRS family of proteins. Mutations in <i>IRS</i> genes are associated with T2DM and susceptibility to insulin resistance.	0.884
IRS2	Insulin receptor substrate 2. Located downstream of <i>INSR</i> in the insulin signaling pathway. Insulin activates <i>INSR</i> , which phosphorylates and recruits different substrate adaptors such as the IRS family of proteins. Mutations in <i>IRS</i> genes are associated with T2DM and susceptibility to insulin resistance.	0.876
MAPK1	Mitogen-activated protein kinase 1; Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements	0.857
PTPN1	Protein tyrosine phosphatase, non-receptor type 1; Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response	0.838
LRRC4B	Leucine rich repeat containing 4B; Synaptic adhesion protein. Regulates the formation of excitatory synapses	0.831
PARL	Presenilin associated, rhomboid-like; Required for the control of apoptosis during postnatal growth	0.829
	ASXL1	
BAP1	BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase); Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Acts as a regulator of cell growth.	0.980
EZH2	Enhancer of zeste 2 polycomb repressive complex 2 subunit. Family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein may play a role in the hematopoietic and central nervous systems	0.979
HCFC1	Host cell factor C1 (VP16-accessory protein); Involved in control of the cell cycle. Regulation of transcription	0.956

SUZ12	SUZ12, polycomb repressive complex 2 subunit. This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial stromal sarcoma.	0.952
UBC	ubiquitin C. The encoded protein is a polyubiquitin precursor. Conjugation of ubiquitin monomers or polymers can lead to various effects within a cell, depending on the residues to which ubiquitin is conjugated. Ubiquitination has been associated with protein degradation, DNA repair, cell cycle regulation, kinase modification, endocytosis, and regulation of other cell signaling pathways	0.946
FOXK2	Forkhead box K2; Recognizes the core sequence 5'-TAAACA-3'. Binds to NFAT-like motifs (purine-rich) in the IL2 promoter. May be involved in both positive and negative regulation of important viral and cellular promoter elements	0.942
FOXK1	Forkhead box K1; Transcriptional regulator that binds to the upstream enhancer region (CCAC box) of myoglobin gene. Has a role in myogenic differentiation and in remodeling processes of adult muscles that occur in response to physiological stimuli.	0.940
OGT	O-linked N-acetylglucosamine (GlcNAc) transferase; Catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins.	0.938
EZH1	Enhancer of zeste 1 polycomb repressive complex 2 subunit. EZH1 is a component of a noncanonical Polycomb repressive complex-2 (PRC2) that mediates methylation of histone H3 lys27 (H3K27) and functions in the maintenance of embryonic stem cell pluripotency and plasticity	0.935
EED	embryonic ectoderm development. This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein mediates repression of gene activity through histone deacetylation, and may act as a specific regulator of integrin function	0.934



Figure 1. Protein-protein interaction (PPI) networks of PTPRF and ASXL1 503

514 Figure legends

- 515
- **Figure 1.** Protein-protein interaction (PPI) networks of *PTPRF* and *ASXL1*.
- 517 PPI networks of (A) *PTPRF* and (B) *ASXL1*. A confidence score is assigned to each
- 518 interaction based upon direct (physical) and indirect (functional) associations.
- 519 Confidence score cut-off was $\geq 0,7$ (high confidence)
- 520